Why agonist Is Trending Today?

- **Lula**, in a speech at Rome, stated that fiscal adjustment programs are not an end in themselves. - AdvanCell will present promising clinical trial results of ADVC001, a novel lead-212-based PSMA-targeted alpha therapy for prostate cancer, at the **ESMO 2025** congress. - **Lupin** has announced it will present phase 1 data on LNP3693, a STING agonist, at the **ESMO Congress 2025**. - **Incyte** will present data on its bispecific TGFβR2×PD-1 antibody and KRAS G12D inhibitor at the **ESMO 2025** congress. - Despite releasing a new album, **Taylor Swift** may not be eligible for a Grammy for the first time since she was 17. - Insolvency applications in Germany increased by 10.4% in September 2025 compared to the previous year, with a 13.4% increase in corporate insolvencies and a 12.9% increase in consumer insolvencies in July 2025 compared to July 2024. - The **ESMO** conference is approaching, and the Hong Kong-listed innovative drug ETF (520690) has declined by over 3.5%, with institutions noting that the trend of innovative drugs going global is long-term. - **Taiho Oncology** and **Cullinan Therapeutics** will present data on Zipalertinib in patients with NSCLC with EGFR mutations and active brain metastases at the **ESMO Congress 2025**. - **Desmond Bryant**, a former NFL player, has endorsed a Miami wellness startup that organizes hikes for executives before a $3,500 reset.